Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Completed 34Recruiting 9Active not recruiting 7Terminated 6Unknown 3Withdrawn 2Not yet recruiting 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 2Lymphoid 2

Conditions

Leukemia, Lymphocytic, Chronic, B-Cell 9Lymphoma, Follicular 5Recurrence 4Lymphoma, Mantle-Cell 4Lymphoma, Large B-Cell, Diffuse 4Lymphoma, B-Cell, Marginal Zone 4Leukemia 4Lymphoma, Non-Hodgkin 3Multiple Myeloma 2Lymphoma 2Hematologic Neoplasms 2Prostatic Neoplasms 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Neoplasms, Plasma Cell 1Lymphoma, B-Cell 1Leukemia, Plasma Cell 1Infectious Mononucleosis 1

Interventions

Rituximab 20Cyclophosphamide 18Etoposide 11Vincristine 10Doxorubicin 10fludarabine phosphate 9Prednisone 9Filgrastim 9Radiotherapy 8Peripheral Blood Stem Cell Transplantation 8Cytarabine 8Methotrexate 7Melphalan 7Dexamethasone 6fludarabine 4Cyclosporine 4Antilymphocyte Serum 4duvelisib 3belinostat 3Thiotepa 3Tacrolimus 3Nivolumab 3Mycophenolic Acid 3Lenalidomide 3Ifosfamide 3Gemcitabine 3Carmustine 3Busulfan 3Alemtuzumab 3sargramostim 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Withdrawn × Lymphoma × Bendamustine Hydrochloride × Clear all
NCT01649622 2012-11-08

Bendamustine in Acute Lymphoblastic Leukemia/Lymphoma (ALL)

M.D. Anderson Cancer Center

Phase 2 Withdrawn
LymphoidOther hematologic neoplasm

Leukemia, Lymphoma, Recurrence, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT01131247 2011-07-20

PH2 Trial in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) With a Combination of Bendamustine & Ofatumumab

Nevada Cancer Institute

Phase 2 Withdrawn
37 enrolled
LymphoidOther hematologic neoplasm

Leukemia, Lymphoma, Lymphoma, Non-Hodgkin, Recurrence, Leukemia, Lymphocytic, Chronic, B-Cell, Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡